

The CATALYST Program: An Overview

Holly Montejano, MS, CIC, CPHQ, VA-BC Director, Clinical Education and Program Development

Brandon Miller Sr. Director, Health Systems



CATALYST Program: Introduction



The **CATALYST** program provides a **collaborative framework to support patient safety** through a focus on scrub the hub **process and outcomes** within a facility.

The program is offered to our customers interested in improving clinical metrics, particularly with central line-associated blood stream infections ("CLABSI").

CATALYST Program: A clinical and sales partnership



Clinical

- Pre- and Post-intervention data sharing for trial units
- Facility clinical assessment (in-person) of trial unit areas
- Monthly cadence calls for performance review
- Internal routine facility auditing for bundle compliance

Sales

- Estimated Par level adjustment (Ex: Prevantics 80% to Alcohol 20%) determined from analysis of 12-month usage history for current scrub-the-hub product(s).
- Vendor-assisted education rollout (LMS, QR codes, in-person, etc.)
- Dedicated Supply chain POC for monthly monitoring of utilization and compliance

PDI BE THE DIFFERENCE® 3

Introducing the **CATALYST** Program.

Be the **catalyst** for infection prevention success.



Our **CATALYST** Program supports our preferred customers in improving clinical metrics, specifically focusing on reducing central line-associated bloodstream infections (CLABSIs). This collaborative framework emphasizes process improvements and outcomes within healthcare facilities.

To show our confidence in the effectiveness of our **Prevantics**® Device Swab, we offer a money-back guarantee to customers in this program. We understand the challenges healthcare providers face in conducting trials, which is why we provide solutions that enhance patient safety and offer peace of mind to our customers.

Join us in being the catalyst to help transform patient safety and clinical outcomes.



CDC estimates

30,000 CLABSIs

occur in ICUs and wards
of acute care facilities
in the U.S. annually¹









- Meet with clinical champion to discuss and analyze real time CLABSI data
- Review current CLABSI policy and practice
- Determine trial unit locations

FACILITY ASSESSMENT & TRIAL INITIATION

- Conduct facility assessment for policy and protocol compliance (required)
- Summarize findings and outline recommendations
- Provide implementation strategies, including education and support







TRIAL IMPLEMENTION

- Track and monitor progress toward CLABSI reduction goals
- Ongoing product education and utilization review
- Ongoing clinical education and consultation



TRIAL CONCLUSION

- Share product success
- Assist facility with standardized product utilization

84,551 - 203,916CLABSIs annually are preventable²

IMPROVED OUTCOMES AND DECREASED COSTS

¹https://arpsp.cdc.gov/profile/nhsn/clabsi

2https://www.ahrq_gov/hai/pfp/haccost2017-results.html#:~:text=Central%20Line%2DAssociated%20Bloodstream%20Infections,-Based%20on%20seven&text=Individual%20studies%20produced%20a%20broad,%2418%2C000%20tox20more%20than%20%2490%2C000 (23,389 x \$48,108 (AHRQ cost avg CLABSI) = \$1.13B)

Thank You!

